2021 Report details for project: Vaccines Task Force

Project name Vaccines Task Force - there are 2 reports for this project: 2021, 2022
Google search Google search on project name (opens in new window) opens in new window
Contracts Contracts search (opens in new window) opens in new window - under development
Organisation BEIS (D1198) - see all reports for this organisation
Report year 2021 (data is from March 2021)
Category Transformation - see all reports for this category
Description: The Vaccine Taskforce (VTF) was set up to drive forward the development and production of a coronavirus vaccine as quickly as possible, bringing together government, academia and industry. The Taskforce was asked to deliver 3 objectives: Secure access to promising vaccine/s for the UK population Make provision for international distribution of vaccines Support industrial strategy by establishing a long-term vaccine strategy plan to prepare the UK for future pandemics The VTF is a team within the Department for Business, Energy and Industrial Strategy (BEIS) consisting of a mix of civil servants, military, external secondees from industry, and contractors. This is to make sure that the Taskforce has access to the deep, specialist expertise in vaccine preclinical and clinical development, regulatory issues, manufacturing and project management necessary to deliver its objectives. As at November 2020, the VTF has just under 200 staff.
DCA (RAG) Amber/Green
DCA text: The Infrastructure Project Authority's Delivery Confidence Assessment rating is Amber/Green.This is primarily due to the following factors: The UK Government's Vaccines Taskforce (VTF) was established to drive forward, expedite and co-ordinate efforts to ensure that the UK population would have access to a clinically safe and effective vaccine against COVID-19.
Start date 2020-03-26
End date 2022-12-31
Schedule text The project end-date is 31 December 2022. This is primarily due to the following factors: The Vaccine Taskforce (VTF) has build a diverse portfolio of vaccines across different formats, and 3 of those are now in deployment. The VTF has shaped new collaborative arrangements to ensure that successful vaccines will be distributed internationally, as well as domestically. the VTF has helped develop COVAX the facility and has shared its expertise to support their global efforts. Furthermore, the VTF has provided targeted funding to support the UK's long-term pandemic preparedness across manufacturing and clinical trials capability. Vaccine deliveries remain robust overall and the VTF continues to meet its delivery targets. The target is to offer a first vaccine dose to JCVI priority cohorts 1-9 by 15 April 2021 and the target to offer a first dose to the whole UK adult population by 31 July 2021 remains on track.
Baseline £2,740.95m
Forecast £1,974.31m
Variance -28.00%
Variance text: The budget variance exceeds 5%. The variance between 'Baseline', taken to be the settlement with Treasury at Spending Review 2020, and current forecasts reflects the significant progress made in finding successful vaccines, the intent now is longer term move to reflect the: 1) The addition of a portfolio of re vaccination projects. 2) Costs originally baselined as falling within 20/21 have moved to 21/22. This is largely due to changes in the accounting treatments on approved drugs,. There has also been some slippage on individual projects within the portfolio.
Whole Life Cost £6,238.14m
WLCost text: The projects Baseline Whole Life Cost is £6238.14m. This is primarily due to the following factors: Costs largely relate to supply agreements for vaccines. Apart from this, there is spend on contracts facilitating vaccine manufacturing, and conducting vaccine development related testing.
Notes1:
Notes2:
Sourcefile IPA_2021.csv

Home Selection Search All Reports Projects +dates Projects +costs Organisations Years Categories


Acknowledgement: GMPP data has been re-used under the Open Government Licence.